Factor VIII-specific CD4+ T-lymphocyte (FVIII-specific CD4+ T-cell) (FVIII-specific CD4+ T-cell)

Factor VIII-specific CD4+ T-lymphocytes are a specialized subset of helper T-cells that play a central role in the immune-mediated rejection of Factor VIII (FVIII) replacement therapy in patients with Hemophilia A (Pratt et al., 1999, Nature Medicine). These cells recognize specific FVIII epitopes presented by Major Histocompatibility Complex (MHC) Class II molecules on the surface of antigen-presenting cells (James et al., 2007, Journal of Thrombosis and Haemostasis). Upon activation, they provide the necessary cytokine environment and costimulatory signals required for B-cells to differentiate into plasma cells that produce neutralizing anti-FVIII antibodies, commonly referred to as inhibitors (Meeks & Batsuli, 2016, Blood). The presence of these inhibitors significantly complicates clinical management by neutralizing the procoagulant effect of infused FVIII, leading to increased morbidity. Therapeutic interventions targeting these T-cells include Immune Tolerance Induction (ITI), which uses frequent FVIII dosing to induce T-cell anergy or deletion, and the use of immunosuppressive agents like Rituximab or Abatacept to disrupt the T-cell-B-cell axis (Lollar & Meeks, 2017, JTH). Research is also focused on developing next-generation tolerogenic therapies, such as engineered regulatory T-cells or nanoparticle-based delivery of FVIII peptides, to specifically silence these reactive T-cells while sparing the rest of the immune system (Mandalà et al., 2021, Frontiers in Immunology).

Other names

Factor VIII-reactive CD4+ T-cellsFVIII-specific T-helper cellsAnti-FVIII CD4+ T-cells

Induction of immune tolerance through T-cell anergy, clonal deletion, or the promotion of regulatory T-cell (Treg) activity to suppress the formation of neutralizing anti-Factor VIII antibodies.